BioMarin Pharmaceutical (BMRN) vs. Its Rivals Financial Contrast
BioMarin Pharmaceutical (NASDAQ: BMRN) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare BioMarin Pharmaceutical to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, earnings, profitability and analyst recommendations.
Risk and Volatility
BioMarin Pharmaceutical has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical’s peers have a beta of 1.28, meaning that their average stock price is 28% more volatile than the S&P 500.
Insider & Institutional Ownership
97.3% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for BioMarin Pharmaceutical and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioMarin Pharmaceutical Competitors||121||762||1630||59||2.63|
BioMarin Pharmaceutical currently has a consensus price target of $113.19, suggesting a potential upside of 31.17%. As a group, “Biopharmaceuticals” companies have a potential upside of 10.87%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher probable upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than its peers.
This table compares BioMarin Pharmaceutical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioMarin Pharmaceutical Competitors||-13,405.09%||38.04%||-20.60%|
Valuation and Earnings
This table compares BioMarin Pharmaceutical and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|BioMarin Pharmaceutical||$1.20 billion||-$106.70 million||-79.17|
|BioMarin Pharmaceutical Competitors||$579.41 million||$241.76 million||-6.62|
BioMarin Pharmaceutical has higher revenue, but lower earnings than its peers. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
BioMarin Pharmaceutical beats its peers on 8 of the 12 factors compared.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.